Biotech M&A Strategies: Deal assessments, trends and future prospects
By: Jeanette Marchant
M&A; activity in the pharma industry continues to gain momentum as a growing number of companies seek to replenish drug pipelines through biotechnology acquisitions. M&As; between biotech companies are also growing in number, stimulated by the drive to strengthen product portfolios and expand participation in the growing global biotech market. Such deal activity is expected to become an increasingly prominent feature in the biotech sector over the next few years. Over 68% of respondents to Business Insights’ recent proprietary survey carried out for this report believe that M&A; initiatives will be integral to the continued success of their company. ‘Biotech M&A; Trends: Deal assessments, trends and future prospects’ is a new report published by Business Insights that analyses trends in biotech M&A; deals valued below $1bn across mid/small-sized pharma and biotech companies, including niche biopharma players and diagnostics/medical technology businesses. Trends in the value, volume and geographical distribution of deals are examined based on M&A; activity since 2003 and a proprietary Business Insights survey reveals how over 130 industry executives perceive the future of biotech M&As.; This report identifies the key factors influencing transactions with an evaluation of over 50 recent deals, in addition to providing a comprehensive case study analysis detailing the strategies behind five major M&A;’s.
Published: October 2008 – Global.